- Hartmann

TheatreNEWS
Issue 1 2010
Disposable Surgical Drapes And Gowns
Safety Is Our First Priority
Sharing Global Experiences
Us Study On Post Operative Infections And Hospitalisation
The HARTMANN Group
A History Based On People And Ideas
FREE PRIZE DRAW
Win £30 M&S Vouchers
2
TheatreNEWS
Welcome
to the 1st Edition of Theatre News
T
his new journal from PAUL HARTMANN Limited aims to publish
articles on topical issues for operating theatres and to share
examples of operating theatre practice across the UK and worldwide.
PAUL HARTMANN Limited, based in Heywood, Lancashire, is part of the
HARTMANN Group, a company with a history of developing innovative
healthcare products since 1818. The enclosed article charts the company’s
progress from its humble beginnings to our global presence today.
Our unique range of Foliodrape surgical disposable drapes and Foliodress
surgical disposable gowns have been developed to offer a high degree of
safety and to support effective infection control. The European Standard
EN 13795 is explained within this issue, and is supported by information on
how the material selection for HARTMANN products ensures that European
standards of performance are exceeded.
As part of our aim to share information on operating theatre practice
across the world, our first issue of Operating Theatre News reviews a study
of the University Hospital of Wisconsin, USA and the additional periods of
hospitalisation and associated costs required for treating postoperative
infections in surgery.
Finally, please do complete the enclosed flyer for your chance to win £30 of
Marks and Spencer vouchers and to receive FREE samples of our Foliodress
Protect A Standard Gown.
Enjoy this issue.
K .Rawlinson
Kim Rawlinson
Business Development Manager
Paul HARTMANN Ltd
[email protected]
See insert to enter our
FREE PRIZE DRAW
and win £30 Marks and Spencer Vouchers
www.HARTMANN.co.uk
1
2
3
190 years of HARTMANN
A history based on people and ideas
190 years ago in Heidenheim, the head quarters of a company was established
which today enjoys global recognition for healthcare and hygiene products.
With almost 9,000 employees in 37 countries and sales of EUR 1.4 billion,
HARTMANN is amongst the leading companies in its industry.
1) Paul HARTMANN’s humble bandage factory
at the so-called “Scheckenbleiche” about 1900.
On the right is the house of the family.
2) View of the packing department in 1935. In
the foreground you can see mull rolls, which
are packed with the aid of the machines.
Attention should be paid to the clean room
environment. The employees even had to wear
hygienic headgear.
3) HARTMANN Exhibition Stand at a medical
congress in Sevilla 1921. The Spanish branch
exhibited clinical equipment and surgical
instruments, which were sold as trading goods.
4) Ludwig von HARTMANN (1766-1852) is the
councillor of commerce, who developed his
factory into one of the biggest cotton mills.
5) His son Paul HARTMANN Senior (18121884) was able to build upon the tradition of
his family and founded his own textile factory,
which focused on the production of dressings.
6) Prof. Victor von Bruns (1812-1883) developed,
together with the chemist Johannes Schmid
from Tuebingen, a procedure of removing grease
from cotton.
7) With his Carbolic Gauze Sir Joseph Lister
(1827-1912) could achieve an important victory
in the battle against infected wounds, which
had limited the possibilities of surgery until
this time.
4
Ludwig von HARTMANN created the basis
for this development in 1818, when he took
over a textile company on the River Brenz.
However, it was his son Paul HARTMANN
Senior who set the company’s course in the
direction of medicine and recognised the
opportunities which lay in the industrial
manufacture of absorbent cotton wool.
Pioneering Medical Developments in the
19th Century
The 19th century is acknowledged as the
beginning of huge advancements in medicine,
as it achieved more for humanity during this
period than the thousands of years before.
The victory over pain through etherisation
and the new findings in bacteriology were
extremely important for medical progress.
These developments made it possible to fight
against infected wounds, which were almost
4
5
always deadly for people during this time.
Sir Joseph Lister (1827-1912) is acknowledged
as the true pioneer, because of his
groundbreaking word on antisepsis.
Alongside, this revolutionary advance
in surgery and wound treatment was the
invention of new dressing materials. To create
a new type of antiseptic wound dressing, Lister,
for example, needed different materials which
had not been used before. The new type of
wound dressing, which was intended for use as
a wound contact layer, consisted of a piece of
silk cloth coated with dextrin and impregnated
with a solution of carbolic acid. It was covered
by a secondary layer of fine gauze impregnated
with carbolic acid, resin and paraffin, the
so-called Lister’s Carbolic Gauze. Another six
layers placed on top of the first two ones were
intended for absorbing exudate.
This helps us to understand why Lister
6
7
190 Years of HARTMANN
was very interested in the cost-effective
manufacture of Carbolic Gauze, in order to
guarantee that his new method became
widely accepted. So he sent a letter to Paul
HARTMANN Senior in Heidenheim with
detailed instructions on 27 April 1874, which
made it possible to begin industrial production
of this new type of dressing material. In the
year before, in 1873,
Paul HARTMANN Senior had already
started with the industrial production of
absorbent cotton wool. Production was
based on the latest findings by surgeon
Prof. Dr. Victor von Bruns in Tübingen, who
had developed a process of making raw
cotton absorbent by removing grease from
cotton wool through boiling it in a 4% soda
lye. Through the years, there have always
been dedicated partners from the fields of
medicine, who have helped initiate product
creations which were further developed
by PAUL HARTMANN. Besides Carbolic
Gauze, this included other products such as
Protective-Silk, Carbolic Silk and Carbolic
Catgut according to Lister, Carbolized Jute
by Bardeleben, Esmarch’s Bandage, and
Jodoform Gauze according to Mikulicz
and Billroth’s evaporating turpentine oil
dressing. At the same time, there was another
trailblazing innovation in the field of hygiene,
which laid the foundations for the production
of modern hygiene products, namely Gustav
Walcher’s invention of highly absorbent
cellulose wadding that could be produced in a
cost-effective manner.
People and their ideas
In Germany there are only a few companies
which have a 190-year-old company history
and family history. After the death of Paul
HARTMANN, his son Paul HARTMANN junior
expanded the factory within 10 years into
a worldwide group with branches in most
industrialised countries. In 1912 Walter
HARTMANN, Paul HARTMANN Junior’s eldest
son, reorganised the expanding company into
a public limited company with the family still
in sole control. New product areas emerged
and the Heidenheim factory began producing
adhesive plasters and lotions developed
in the recently completed pharmaceutical
department.
In 1936 the HARTMANN brand became
increasingly familiar to consumers thanks to
contemporary advertising and a catchy slogan
“HARTMANN helps healing” which remains
the Group slogan today.
A raft of innovative product developments
shaped the following years. For example: in
1938 HARTMANN developed its first ointment
dressing, Branolind, specially designed to avoid sticking to
the wound and thus reduce the pain of dressing changes. In
1964 Pur-Zellin, a perforated cellulose swab specially designed
to retain its shape, was launched and is still used in many
GP surgeries today. In 1965 the safety in operating theatres
was redefined due to an interwoven X-ray detectable thread
called Telatrast. In 1967 there was the first gauze compress
with folded in cut edges, which is free from intrusive
threads around the edges. As ES-Kompresse,
it became a classic gauze
swab in the treatment
of wounds. In 1974
the incontinence insert
pad MoliNea Plus D was
launched and paved the
way for the market entry
in continence care. In the
meantime HARTMANN
became one of the leading
companies in Europe with its
brands like MoliCare, MoliForm
and MoliMed continence
care products. In 1976 the
development
of disposable drape sheets under
the Folioplast brand laid the foundation for a whole new
product area: disposable drape sheets designed to prevent
infection.
Dressings, hygiene and healthcare products support
the daily work of all health care professionals and perform
important therapeutic tasks. This is one of the reasons,
why the history of HARTMANN is closely connected to
the progress of medicine and health care. So the dialogue
between science and practice has always been and will
remain an important part of the HARTMANN company
8
10
TheatreNEWS
Examples of products of the HARTMANN
product range from several decades:
8) Different tampons for use in
gynaecology (from the price list of 1909)
9) The suture material Pehafil was proven
to be chemically and mechanically nonirritant (about 1960).
10) Headgear supplied with easily
replaceable cellophane inserts to avoid
airborne infection (about 1960).
11) Scrubs with and without sleeves made
of strong cotton cloth or strong linen,
which certainly made the OP-team sweat
(from the price list of 1909).
9
11
5
Products and Services
www.HARTMANN.co.uk
HARTMANN disposable
operating theatre systems
A Safety First Approach
Today’s high operating theatre standards stand and fall with
the hygienic measures that are adopted for the prevention of
infection. Sterile draping of the patient, their surroundings
and the wearing of sterile operating theatre clothing are
essential components of effective infection control.
THERE CAN BE NO COMPROMISE ON SAFETY. However, safety
does not preclude economy, as demonstrated by HARTMANN
disposable operating theatre systems.
Draping materials and operating theatre
clothing are used to protect against infections and
are therefore regarded legally as medical products.
Their production and quality testing are
subject to European Standard EN 13795. The
most important test methods relate to the
material properties which are essential for
reliable protection against infection:
• Particle release (linting) (ISO 9073-10),
• Resistance to liquid penetration
(European Standard EN 20811)
• Wet microbial penetration
(European Standard EN ISO 22610).
Nonwoven fabrics – especially the
innovative Spunbound-MeltblownSpunbound material (SMS), from
which HARTMANN operating
theatre clothing are manufactured
– and the composite materials
from film and nonwoven for
the surgical drapes, fulfil these
requirements perfectly.
Material safety and the associated
Not every operation has the same risk of infection. This
means that draping materials and operating theatre
clothing can only be used economically when they
correspond exactly to the respective surgery-specific
requirements in material quality and product design.
HARTMANN disposable operating theatre systems offer
economical alternatives at the highest level of safety.
6
high level of protection against infection are
certainly the most important of many reasons
why draping materials and operating theatre
clothing made of nonwoven fabric are often
preferred to reusable textile systems. Moreover,
the reprocessing of reusable textile systems is a
sophisticated, cost-intensive undertaking.
Two European Standard
performance levels Part 3 of European standard EN 13795,
published in August 2006, among other
things classifies medical products in two
performance levels: High Performance and
Standard Performance.
According to the requirements of these
performance levels, HARTMANN can provide
different material qualities and product
designs, to respond to the risk of infection
specific to surgery. If, for example, the
operation is only of short duration and large
amounts of body fluids are not to be expected,
for sterile draping it is possible to use a
cost-effective, but always protective two-layer
material instead of a three-layer material.
Furthermore, HARTMANN can also meet
the various hygienic requirements for individual
operations with special product designs.
A good example of this is the disposable
surgical gown Foliodress gown urology. In
urological operations, there are very large
TheatreNEWS
HARTMANN disposable operating theatre systems
amounts of body fluids, therefore the gown is
provided with a fluid impermeable PE film under
the chest area, for reliable protection of the
surgeon against potentially infectious material
and fluids.
Accordingly, the HARTMANN range
of disposable operating theatre products
includes a large number of products in various
materials and designs, which meet both
the high hygienic requirements for effective
protection against infection and the necessary
economic concerns.
Foliodrape surgical drapes – two material
variants for all cases
The fact that Foliodrape functions so well
not only as a reliable barrier to infection, but
also with respect to economical use, is due to
the two different material variants Foliodrape
Comfort and Foliodrape Protect:
• The three-layer material of Foliodrape
Comfort is designed for all operations of
long duration and for operations involving
large amounts of body fluids. The material
properties of Foliodrape Comfort exceed all
high-performance requirements in European
standard EN 13795.
• The two-layer material of Foliodrape
Protect is designed for short operations in
the inpatient and outpatient area, involving
small amounts of body fluids. The material
properties of Foliodrape Protect also meet all
high-performance requirements in European
standard EN 13795.
In addition, there are also a great variety of
Foliodrape drapes, which makes a substantial
contribution to economical use. The available
products include complete sets for frequent
surgical indications, special drapes.
moisture and bacteria migration. Owing to the
firm bonding of the fibres, it is particularly lowlinting and abrasion-resistant, yet extremely
soft and breathable, providing excellent
wearing comfort.
HARTMANN have a gown tailored to the
particular needs of the procedure with its
three product lines:
Foliodress Protect – available in reinforced
NEW Foliodress Protect A – available in
standard
Foliodress gown Comfort - available in
reinforced and standard
For example, Foliodress gown Protect A
Standard is suitable for operations of shorter
procedures involving small quantities of fluid.
Foliodress Protect Reinforced has reinforced
sleeves and chest area and is suitable for
longer operations involving moderate to large
quantities of fluids.
The range is completed by the Foliodress
operating scrub theatre clothing. It consists
of tunic and trousers and also complies
with European Standard EN 13795. With its
very attractive price, it also contributes to
economical use.
Below: Some examples from the large Foliodrape
and Foliodress range. The individual products can be
assembled in the Foliodrape CombiSets as required.
1
A
2
3
4
B
5
A) Foliodrape Comfort, three-layer, with an outermost
low-particle viscose-nonwoven in 3D “orange skin
structure” (1) for rapid absorption of fluids, an absolutely
germproof intermediate layer of polyethylene film (2) and
the bottom layer of a soft polypropylene nonwoven (3) for
greater patient comfort.
B) Foliodrape Protect, two-layer, consisting of a lower
impermeable layer of polyethylene film (5) and an SMS
(Spunbound – Meltblown – Spunbound) surface layer
(4), which binds fluid quickly, drapes well and has a low
number of particles.
Foliodress operating theatre clothing
– always to be used economically
Also for the Foliodress range of disposable
surgical gowns and disposable operating
theatre scrub clothing, without detriment to
safety and wearing comfort it is always possible
to select operating theatre clothing that is
adequate for the hygienic requirements of the
planned operation. This saves costs. Of course,
all products comply with standard EN 13795 (13) of the European Standard for surgical gowns
and operating theatre clothing.
Foliodress disposable surgical gowns are
made from the innovative SMS (Spunbound
– Meltblown – Spunbound) -nonwoven
polypropylene fabric, which guarantees
optimum quality: the nonwoven fabric material
is fluid-repellent and provides high resistance to
7
Medicine and Sciences
www.HARTMANN.co.uk
The costs of postoperative infections
Additional periods of hospitalisation
are expensive
A study of the University Hospital of Wisconsin, USA,
shows that the additional period of hospitalisation
that is required for treating postoperative infections
in surgery represents a decisive cost factor.
A correlation between period of hospitalisation and
costs on the one hand, and the localisation of the
infection on the other, can also be demonstrated.
A contribution from Hardy-Thorsten Panknin, Badensche Straße 49, D-10715 Berlin Germany
Email: [email protected]
Co-author: Prof. Dr. med. Bernd Reith, Chief Physician of the Surgical Clinic, Klinikum Konstanz
(Constance Hospital), Luisenstraße 7, D-78464 Konstanz Germany
Even with careful observance of hygiene standards and
execution of the usual antibiotic prophylaxis, after elective
surgical procedures there is infection at the surgical site
in approx. 1-5 % of cases. For the patients affected this
means prolongation of their pain and functional restrictions
– even if there are no more serious consequences, such as
reoperations, losses of limbs or organs or in the worst case,
death owing to uncontrollable infection.
As well as surgical site infections, however, other
infectious complications are also possible. Urinary
catheterisation that is often associated with surgery can
lead to a nosocomial urinary tract infection, and prolonged
assisted ventilation in the intensive care unit can lead to
ventilator-associated pneumonia. Such complications also
prolong hospitalisation, necessitating further diagnostic and
Prolongation of hospitalisation
Table 1
Period of hospitalisation in days
(25th-75th percentile)
8
Patients with fatal
underlying disease
Infection type
Patients with nonfatal underlying
disease
Surgical site infection
8 (5-13)
8 (5-14)
Nosocomial infection at some
other site
10 (6-21)
8 (5-14)
No infection
5 (3-7)
5 (3-7)
therapeutic measures and leading in some circumstances to
secondary injuries. For the hospital, postoperative infections
on the one hand mean a recognisable quality problem, and
on the other hand, the necessary follow-up treatments lead
to increased costs. Hospital managements should therefore
at least determine how the costs arising from individual
complications are correlated, so that the preventive
measures provided by the hygiene team can be directed first
at the most cost-intensive infections.
Wound infections and other infections in the
postoperative phase
An American study with a large number of surgical
patients aimed to analyse the costs of postoperative
surgical site infections (“wound infections”) in relation to
other nosocomial infections in the postoperative phase.
The data originated from a study that was carried out
towards the end of the 1990s at the University Hospital
of Wisconsin, USA, the original purpose of which was
to evaluate the effect of nasal decolonisation treatment
with mupirocin on the postoperative infection rate. At
that time, the data showed only a very limited effect of
such decolonisation treatment, so that general mupirocin
prophylaxis can be considered since then as out-dated.
The extensive clinical data was then used again in 2006,
to evaluate the relations between the pre-operative
pathological state and subsequent infectious complications
TheatreNEWS
The costs of postoperative infections
(Herwaldt LA et al., A prospective study of outcomes,
healthcare resource utilisation, and costs associated with
postoperative nosocomial infections. Infect Control Hosp
Epidemiol 2006;27:1291-1298).
Results
Of the 3,864 patients who were included in the mupirocin
study, 2,408 (62.3 %) underwent general surgery,
732 (18.9 %) underwent neurosurgery and 724 (18.7
%) underwent cardiac surgery. Postoperatively, 438
(11.3 %) patients developed at least one nosocomial
infection. 316 of these infections were postoperative
surgical site infections, and in addition there were 54
urinary tract infections, 43 respiratory tract infections
and 18 septicaemias. The commonest pathogens were
staphylococci, at 40% of all isolates. 11 of the 438
patients with nosocomial infection (2.5 %) died. The
mortality of these infected patients was far higher than for
patients without infection (45 of 3,425 = 1.3 %), but the
difference was not statistically significant.
Costs of treatment for postoperative infections
The authors also investigated the direct costs of treatment
for postoperative infections. Such a cost analysis is easier in
the US-American health care system, because each individual
therapeutic measure is charged to the health insurer. In
addition, the prolonged period of hospitalisation makes a
difference to the respective daily basic charge (Table 1).
It was found that the period of hospitalisation for
nosocomial infection away from the surgical site was, at an
average of 10 days, significantly longer than for patients
with postoperative surgical site infection (average period
of hospitalisation 8 days) and relative to patients without
infection (average period of hospitalisation 5 days, in
each case p < 0.001). For patients with fatal underlying
disease the prolongation of hospitalisation was the same
with both types of infection. An important observation
was that ultimately the prolongation of hospitalisation for
patients with fatal underlying diseases was no greater than
for patients with other underlying diseases or without an
underlying disease.
Owing to the prolongation of hospitalisation, but also
owing to the diagnostic and therapeutic measures in
connection with the infections, there were marked cost
increases, shown as relative values in Table 2. It can be
seen that infections away from the surgical site, both in
general surgery and in cardiac surgery and neurosurgery,
were much more expensive than surgical site infections.
It was only in the case of cardiac surgery patients with
fatal underlying diseases that such a difference could not
be demonstrated. For some subgroups (e.g. general surgery,
infection away from the surgical site), the cost increases
reached values up to 344 % above the reference costs for a
45-year-old, healthy comparative patient with the same type
of surgery, but without postoperative infection.
Conclusions
Postoperative infections in surgical patients lead to a prolongation of hospitalisation
of on average 3-5 days, and the patient’s underlying disease (fatal, non-fatal)
does not play a large role. What is decisive for the degree of prolongation of
hospitalisation is rather the question whether the infection is at the surgical site or
whether it is a nosocomial infection at some other site (e.g. ventilator-associated
pneumonia, septicaemia). The costs were also significantly higher for infections that
did not relate to the surgical site.
The study uncovers two interesting aspects: on the one hand, the average
prolongation of hospitalisation was not as pronounced as would be expected with
severe infections. One possible reason for this is that the outpatient sector and
the inpatient sector are closely interlinked in the US-American health care system,
so that even if there is a continuing need for therapy (antibiotics, laboratory tests,
X-rays) the patient can be discharged – as a rule in the hospital’s own outpatient
department. In this way, the primary carers do not lose contact with the patient and
can if necessary arrange for readmission, if the infection does not subside. On the
other hand, it was clear from the study that infections away from the surgical site
cost considerably more than surgical “wound infections”.
The explanation is presumably that ventilator-associated pneumonias and
septicaemias associated with venous catheters as a general rule develop during
therapy in intensive care units and therefore the prolongation of hospitalisation
takes place in the (more expensive) intensive care unit. Presumably, therefore, those
patients are affected who already have underlying diseases that are more prone to
complications; however, this relationship was not analysed in detail by the authors.
However, what is important for hygiene management is the conclusion that
infections such as ventilator-associated pneumonias and septicaemias associated
with venous catheters are presumably the largest cost factors and therefore hygiene
regimens should take precedence in the prevention of such complications.
Percentage cost increase
Table 2
Cost increase in % ± standard error*
Surgical site infection
(“surgical wound
infection”)
Infection at some
other site
General surgery
Non-fatal underlying disease
Fatal underlying disease
82.9 ± 16.7 (s)
105.6 ± 23.9 (s)
344.2 ± 68.3 (s)
171.1 ± 46.8 (s)
Cardiac / thoracic surgery
Non-fatal underlying disease
Fatal underlying disease
25.2 ± 13.8 (ns)
40.8 ± 22.1 (ns)
95.9 ± 34.8 (s)
19.5 ± 27.3 (ns)
Neurosurgery
Non-fatal underlying disease
Fatal underlying disease
60.8 ± 32.1 (ns)
80.9 ± 42.2 (ns)
306.7 ± 90.5 (s)
148.2 ± 67.1 (s)
Type of surgery
* the hospital costs for a 45-year-old patient of normal weight without underlying diseases,
without pre-operative infection and with a pre-operative period of hospitalisation of 1 day were
taken as the reference value. These “reference costs” came to 1,899 US-$ for general surgery,
3,400 US-$ for cardiac or thoracic surgery and 2,226 US-$ for neurosurgery.
s = significant cost increase relative to reference value, ns = cost increase not significant
9
Hydrofilm® Plus
High MVTR Transparent film dressing
with absorbent pad.
Reliable protection of exuding wounds.
By introducing Hydrofilm® Plus, HARTMANN have complimented their range of modern and traditional wound care products with
a cost effective, self adhesive, transparent film dressing with pad, which exactly meets the needs of post op wound management.
The pad itself is Cosmopor® E – viscose fibres coated with an anti-adherent polyethylene net.
Application - Easy as 1, 2, 3, 4
With its four stage application process Hydrofilm® Plus
makes for simple, time saving application.
Strong yet Sensitive
OF
O
R
P
R
WATE opor® E
Cosm
The acrylic, hypoallergenic adhesive provides
maximum security, whilst being tolerated by patients
with sensitive skin. The polyurethane film material is
extremely thin and elastic which means the dressing
will adapt to body contours and can be removed
painlessly without damaging new epithelium.
10
For further information: Telephone 01706 363200,
Email: [email protected]
www.HARTMANN.
TheatreNEWS
www.HARTMANN.co.uk
New HARTMANN
Great Britain Website
A new year brings a new look to the HARTMANN Great Britain
website, which has been redesigned to promote our extensive
range of products and added value services. The new look
website can be viewed at www.HARTMANN.co.uk.
You can search for detailed product information by selecting the appropriate
product category (Wound Management, Continence Management and
Operating Theatre Products) and then selecting Unique Products. In addition,
why not download HARTMANN publications, literature and clinical studies
direct from the website.
We would welcome your comments on the new website and your
suggestions for its further development. Please send your comments to
[email protected]
Denise Murray joins the HARTMANN
Operating Theatre Products Division
We are pleased to confirm that Denise Murray has joined the
Operating Theatre Products Division of PAUL HARTMANN Limited.
As Territory Sales Manager, Denise will cover the North West Territory
promoting our unique range of disposable operating theatre surgical
drapes and theatre clothing. Christopher Boaler has undertaken this
role previously but will now become the North West Territory Sales
Manager for the Wound Management Division.
Denise qualified as a nurse in 1983 at Salford Health Authority and commenced her
career as a scrub nurse covering many specialties. Denise comments “I wanted to
work for HARTMANN as it is such a well established company with a long history
and worldwide presence. There are many unique products and some interesting
innovations which as an ex-theatre nurse, I would love to have access to. This new
position enables me to combine my theatre experience with the product knowledge
of our extensive range. My aim is to be recognised as the face of HARTMANN for
operating theatre products in the North West and for my customers to believe that I
will go the extra mile to meet their needs”.
We wish Denise every success at PAUL HARTMANN Limited as we believe she will
become an invaluable support to our existing and new customers.
Denise Murray can be contacted on 07967 676335 or by email at
[email protected]
11
Working together to make a difference
Risk prevention requires a team effort
The risk of infection during surgical procedures places a heavy responsibility on
surgeons, operating department practitioners and theatre staff.
Hence the need for a professional partner able to supply high quality protective
materials designed to maximise patient care and protect theatre staff.
At HARTMANN, our theatre products are based on innovative, patented technology,
which combines maximum infection control with time-saving practicality. As a key
supplier to the NHS, our full range of drapes and gowns are available on national
contract, making them easy to obtain as well as reliable and effective.
PAUL HARTMANN Limited, Heywood Distribution Park, Pilsworth Road, Heywood, Lancashire. 0L10 2TT
Tel: 01706 363200 Fax: 01706 363201 Web: www.HARTMANN.co.uk E-mail: [email protected]